-

Caribou Biosciences to Participate in Three Upcoming Investor Conferences in March

BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today that Rachel Haurwitz, Ph.D., Caribou’s President and Chief Executive Officer, will present a company overview at upcoming investor conferences in March.

  • Barclays Global Healthcare Conference on Tuesday, March 9, 2021 at 1:15 p.m. ET
  • Spring Private Company Showcase hosted by Solebury Trout, Credit Suisse, and Cooley on Thursday, March 11, 2021 at 11:40 a.m. ET

A live and archived webcast of the presentations will be accessible via Caribou’s website at https://cariboubio.com/news/events for 30 days following the events.

Additionally, the company will participate in meetings during the SVB Leerink Biopharma Private Company Connect conference occurring from March 25-26, 2021.

About Caribou’s Pioneering Next-Generation CRISPR Platform

CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Type II CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to editing at the targeted genomic site. CRISPR systems occasionally edit unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function.

In response to this challenge, Caribou has developed chRDNAs (pronounced “chardonnays”), highly specific RNA-DNA hybrid guides that direct substantially more precise genome editing than all-RNA guides. chRDNAs drive highly specific, multiplex genome editing including gene insertion. Caribou uses chRDNA guides in concert with various CRISPR enzymes to develop complex immune cell therapies.

Caribou is deploying chRDNAs to power the development of its CRISPR-edited therapies by guiding cellular editing with the highest level of fidelity.

About Caribou Biosciences, Inc.

Caribou is a leading clinical-stage CRISPR genome editing biotechnology company founded by pioneers of CRISPR biology, including Nobel Prize winner Jennifer Doudna. The company is developing an internal pipeline of off-the-shelf genome-edited CAR-T and CAR-NK cell therapies.

For more information about Caribou, visit www.cariboubio.com and follow the company @CaribouBio.

“Caribou Biosciences” and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.

Contacts

Caribou Biosciences Media Contact:
Greg Kelley
Ogilvy
gregory.kelley@ogilvy.com
617-461-4023

Caribou Biosciences Investor Relations Contact:
Sylvia Wheeler
Wheelhouse LSA
swheeler@wheelhouselsa.com

Industry:

Caribou Biosciences, Inc.

Release Versions
English

Contacts

Caribou Biosciences Media Contact:
Greg Kelley
Ogilvy
gregory.kelley@ogilvy.com
617-461-4023

Caribou Biosciences Investor Relations Contact:
Sylvia Wheeler
Wheelhouse LSA
swheeler@wheelhouselsa.com

More News From Caribou Biosciences, Inc.

Caribou Biosciences Announces Closing of Upsized Initial Public Offering

BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the closing of its previously announced initial public offering of 19,000,000 shares of common stock, at a price to the public of $16.00 per share. In addition, Caribou has granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less the under...

Caribou Biosciences Announces Pricing of Upsized Initial Public Offering

BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the pricing of its upsized initial public offering of 19,000,000 shares of common stock at a public offering price of $16.00 per share. All of the shares of common stock are being offered by Caribou. The gross proceeds of the offering, before deducting underwriting discounts and commissions, and other offering expenses payable by Caribou, are ex...

Caribou Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial Evaluating CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that the first patient has been dosed in its open-label, multicenter ANTLER phase 1 clinical trial (NCT04637763) to evaluate the company’s lead product candidate, CB-010, in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). CB-010 is an allogeneic anti-CD19 CAR-T cell therapy derived from healthy donor T cells that ha...
Back to Newsroom